Literature DB >> 12714833

Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease.

Giuseppe Patti1, Andrea D'Ambrosio, Aldo Dobrina, Giordano Dicuonzo, Carlo Giansante, Nicola Fiotti, Antonio Abbate, Gianfranco Guarnieri, Germano Di Sciascio.   

Abstract

BACKGROUND: Increased plasma levels of acute phase reactants are correlated with acute coronary syndromes and increased risk of in-hospital events. Interleukin-1 receptor antagonist (IL-1Ra) modulates the activity of IL-1, a cytokine associated with inflammatory response; we have prospectively investigated whether detection of increased levels of IL-1Ra in patients may be useful in the characterization of coronary syndromes.
METHODS: Plasma levels of IL-1Ra were measured in 118 consecutive patients undergoing coronary angiography with a clinical diagnosis of recent unstable angina (N = 57), chronic stable angina (N = 49) or atypical chest pain (N = 12).
RESULTS: Angiography showed significant coronary disease in the first two groups and was normal in the latter group. Patients with unstable angina had significantly higher levels of IL-1Ra than stable patients [158 (110-224) vs 108 (95-154) pg/ml, P = 0.002] and individuals with chest pain and normal coronary angiogram [110 (97-123) pg/ml, P: = 0.038]. In contrast, while C-reactive protein levels were significantly higher in patients with stable and unstable angina vs those without coronary disease (0.29 vs 0.06 mg/dl, P: = 0.022), they did not discriminate between stable and unstable angina patients (0.22 vs 0.32 mg/dl, P: = 0.66).
CONCLUSIONS: These results indicate that IL-1Ra may be a sensitive marker of clinical instability in patients with coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12714833     DOI: 10.1023/a:1023284912712

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

Review 1.  Inflammatory markers of ischemic coronary syndromes.

Authors:  A Manzoli; G Patti; G Di Sciascio
Journal:  Ital Heart J       Date:  2001-09

2.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

Review 3.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

4.  Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra.

Authors:  M D Josephs; C C Solorzano; M Taylor; J J Rosenberg; D Topping; A Abouhamze; S L Mackay; E Hirsch; D Hirsh; M Labow; L L Moldawer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-04       Impact factor: 3.619

5.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events.

Authors:  L M Biasucci; G Liuzzo; G Fantuzzi; G Caligiuri; A G Rebuzzi; F Ginnetti; C A Dinarello; A Maseri
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

6.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.

Authors:  E Fischer; K J Van Zee; M A Marano; C S Rock; J S Kenney; D D Poutsiaka; C A Dinarello; S F Lowry; L L Moldawer
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

7.  Inflammatory markers and coronary interventions: a potentially useful follow-up modality after stenting.

Authors:  Giuseppe Patti; Germano Di Sciascio; Andrea D'Ambrosio; Giordano Dicuonzo; Antonio Abbate; Aldo Dobrina
Journal:  Catheter Cardiovasc Interv       Date:  2002-07       Impact factor: 2.692

Review 8.  Biologic basis for interleukin-1 in disease.

Authors:  C A Dinarello
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

9.  Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy.

Authors:  L Airaghi; M Lettino; M G Manfredi; J M Lipton; A Catania
Journal:  Am Heart J       Date:  1995-08       Impact factor: 4.749

10.  Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene.

Authors:  M J Nicklin; D E Hughes; J L Barton; J M Ure; G W Duff
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  6 in total

Review 1.  Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.

Authors:  Razi Khan; Eric Rheaume; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2018-09-15       Impact factor: 5.113

2.  Increased inflammatory markers in brain and blood of rats subjected to acute homocysteine administration.

Authors:  Aline A da Cunha; Andréa G K Ferreira; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2010-04-28       Impact factor: 3.584

3.  Inflammatory cytokines imbalance in the very early phase of acute coronary syndrome: correlations with angiographic findings and in-hospital events.

Authors:  Natale Daniele Brunetti; Irene Munno; Pier Luigi Pellegrino; Vincenzo Ruggero; Michele Correale; Luisa De Gennaro; Andrea Cuculo; Erasmo Giulio Campanale; Matteo Di Biase
Journal:  Inflammation       Date:  2011-02       Impact factor: 4.092

4.  Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

Authors:  Nihat Ozer; Burak Tangurek; Fatih Firat; Songul Ozer; Zeynep Tartan; Recep Ozturk; Batuhan Ozay; Figen Ciloglu; Hale Yilmaz; Nese Cam
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

Review 5.  Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes.

Authors:  Jennifer A Rymer; L Kristin Newby
Journal:  JACC Basic Transl Sci       Date:  2017-08-28

6.  Association of C-reactive protein, interleukin-1 receptor antagonist and adiponectin with the metabolic syndrome.

Authors:  Juha Saltevo; Mauno Vanhala; Hannu Kautiainen; Esko Kumpusalo; Markku Laakso
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.